DeutschNewstral
Article
jdsupra.com on 2024-05-03 20:04
Biosimilar Launch and Approval Updates – Tyenne® (tocilizumab-aazg), Xlucane™ (ranibizumab), Hercessi™ (trastuzumab-strf)
Related news
- Fresenius Kabi Announces Launch of TYENNE, a Tocilizumab Biosimilar Referencing ACTEMRAjdsupra.com
- Fresenius Kabi Announces FDA Approval of TYENNE, a Tocilizumab Biosimilar Referencing ACTEMRAjdsupra.com
- STADA and Xbrane Announce Approval of Ranibizumab Biosimilar in Europejdsupra.com
- Biologic and Biosimilar Approval Updatesjdsupra.com
- Biogen Announces FDA Approval of TOFIDENCE, a Tocilizumab Biosimilar Referencing ACTEMRAjdsupra.com
- FDA Approves Celltrion’s Trastuzumab Biosimilarjdsupra.com
- Ranibizumab Biosimilar Program Updatesjdsupra.com
- FDA Accepts for Review Fresenius Kabi’s BLA for Tocilizumab Biosimilarjdsupra.com
- Recent Adalimumab Biosimilar Updatesjdsupra.com
- Fresenius Kabi’s Actemra® biosimilar Tyenne® (tocilizumab-aazg) Approved in the U.S.jdsupra.com
- Celltrion Submits an aBLA for Actemra® (tocilizumab) Proposed Biosimilar CT-P47jdsupra.com
- Approval of Denosumab biosimilar and launch of teriparatide biosimilar in China and South Koreajdsupra.com
- Denosumab Biosimilar Updates - June 2024jdsupra.com
- International Biosimilar Approval and Launch Updates - April 2022jdsupra.com
- Sandoz submits BLA for proposed biosimilar trastuzumab to the FDAjdsupra.com
- New BPCIA Complaint: Genentech Sues Amgen over Proposed Trastuzumab Biosimilarjdsupra.com
- Mylan-Biocon Publish Positive Results for Proposed Trastuzumab Biosimilarjdsupra.com
- International Biosimilar Approval and Launch Updates - February 2022jdsupra.com
- Mylan and Biocon Gain Approval for Trastuzumab Biosimilar in Braziljdsupra.com
- Teva and Celltrion Launch Trastuzumab Biosimilar in U.S.jdsupra.com